bristol-myers glp-1 receptor agonist products Five Unexpected New Uses for Agonists Repurposing glucagon-like peptide-1 receptor agonists

In a study on Medicaid recipients, Jerrell found that black children with obesity had more diagnosed medical conditions but received less health care than non-black children [213]

The two main incretins are GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide, previously called gastric inhibitory polypeptide)

These milestones highlight the growing regulatory and clinical momentum supporting expanded uses Ongoing trials are also exploring the impact of GLP-1 agonists on cardiovascular outcomes, liver health, and even neurodegenerative diseases, reinforcing their value in treating systemic metabolic disorders

Histologically, lobular inflammation with hepatocyte ballooning in zone 3 is typical of adult MASLD (type 1 MASH)

Efinopegdutide (JNJ-64565111